Compare Merck & Co., Inc. (MRK) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Orion Office REIT Inc — how do they compare? Merck & Co., Inc. trades at $133.35 (market cap $327.94B), while Orion Office REIT Inc trades at $2.83 (market cap $161.44M). The key difference: Merck & Co., Inc. is far larger — about 2031.3× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| MRK | ONL | |
|---|---|---|
Market Cap | $327.94B | $161.44M |
Sector | Health | Real Estate |
52-Week High | $132.93 | $3.04 |
52-Week Low | $77.60 | $1.93 |
Enterprise Value | $374.70B | $578.37M |
Dividend Yield | 2.56% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters with Q3 2026 results pending. Revenue grew to $65.01B in 2025 with net income of $18.25B, though 2026 projections show lower profitability. Recent acquisition activity includes the $6.7B tender offer for Terns Pharmaceuticals to bolster oncology pipeline.
Merck maintains solid fundamentals with 67.6% analyst buy ratings and $140.58 consensus target, offering 7.8% upside. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The stock presents a balanced opportunity with strong institutional support but faces margin compression headwinds in 2026.
ONL trades at $2.83, up 2.91% with a bullish technical signal and strong moving average support. The company reported mixed Q2 2026 results with an EPS beat but continues to face fundamental challenges including declining revenue from $208M in 2022 to $148M in 2025 and negative net margins. Recent news highlights strategic review progress and portfolio repositioning efforts.
The outlook remains cautious despite technical strength. While the stock shows bullish momentum and pays consistent dividends, persistent revenue declines, negative profitability metrics, and high debt levels pose significant risks. Analyst sentiment is evenly split between Buy and Hold recommendations, reflecting uncertainty about the company's turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
